Table 2 Baseline Characteristics of The Study Population
Total | Control | Ergocalciferol | p value | |
|---|---|---|---|---|
(n = 186) | (n = 79) | (n = 107) | ||
Demographics (mean ± SD) | ||||
Age, y | 57.6 ± 13 | 55.2 ± 11.9 | 59.4 ± 13.2 | 0.01 |
Male, no. (%) | 92 (49.5) | 40 (50.6) | 52 (48.6) | ns |
Vintage, y | 5.9 ± 4 | 6.3 ± 4.1 | 5.6 ± 3.2 | ns |
Co-Morbidities, number (%) | ||||
Diabetes | 128 (68.8) | 51 (64.6) | 77 (72) | ns |
CAD | 90 (48.4) | 52 (65.8) | 38 (35.3) | <0.001 |
Hypertension | 172 (92.5) | 72 (91.1) | 100 (93.5) | ns |
CVA | 23 (12.4) | 3 (3.8) | 20 (18.7) | 0.003 |
Cancer | 7 (3.8) | 1 (1.3) | 6 (5.6) | ns |
Laboratory Parameters (mean ± SD) | ||||
Vitamin D level, ng/ml | 16.8 ± 7 | 19.2 ± 6.8 | 16.2 ± 7.5 | 0.03 |
Hemoglobin, g/dl | 11.1 ± 1 | 11.2 ± 1.1 | 11 ± 1.4 | ns |
TSAT, % | 31.6 ± 16 | 27.5 ± 10 | 34.7 ± 18 | <0.001 |
Ferritin, mg/dl | 665 ± 383 | 538 ± 269 | 759 ± 425 | <0.001 |
Calcium, mg/dl | 9.1 ± 1 | 9.2 ± 0.7 | 9.1 ± 0.7 | ns |
Phosphorus, mg/dl | 5.2 ± 2 | 5.1 ± 1.4 | 5.3 ± 1.7 | ns |
PTH, pg/ml median [IQR] | 294 [178, 428] | 283 [162, 408] | 308 [184, 490] | ns |
Albumin, mg/dl | 4.1 ± 0.01 | 4.2 ± 0.4 | 4 ± 0.3 | ns |
Medications (median [IQR]) | ||||
Iron sucrose, mg/month | 200 [0,287] | 200 [25,400] | 150 [0,250] | ns |
EPO, IU/Month | 26000 [12175, 48000] | 26000 [12350, 49450] | 27500 [13200, 48000] | ns |
Paricalcitol, μg/month | 26 [12, 39] | 26 [10.5, 42] | 25 [12.5, 39] | ns |